Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 18, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on September 15, 2020 , the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
SAN DIEGO , Sept. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.  (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC)   - Significant unmet need for new effective oral therapies in UC SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.  (Nasdaq: ARNA) today announced that that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Virtual Healthcare Conference – Presenting on Wednesday, September 9 , at 1:20 PM
View HTML
Toggle Summary Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderate-to-severe alopecia areata   - There are currently no FDA-approved treatments for alopecia areata SAN DIEGO , Sept. 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Aug. 19, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on August 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 15,275 shares of its common stock
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , July 17, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 15, 2020 , the Compensation Committee of its Board of Directors granted to six new employees inducement stock options to purchase an aggregate of 35,850 shares of its common stock and
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , June 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on June 15, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 80,250 shares of its common stock to 12 new employees and
View HTML
Toggle Summary Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global clinical
View HTML
Toggle Summary Arena Pharmaceuticals Announces R&D Leadership Transition
- Dr. Preston Klassen, Executive Vice President, Head of Research and Development, resigning   - Dr. Chris Cabell appointed Executive Vice President, Head of Research and Development, and Chief Medical Officer SAN DIEGO , June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
View HTML